

### Q3. Ongoing Extramural Research Projects April 2016 - March 2017

No.	Name of PI	Project Title	Funded by
<b>Biochemistry Research</b>			
1	Dr Prabhudas Patel Dr Ava Desai Dr Shilpa Patel	Prevalence of high risk human papilloma virus type 16 and 18 in cervical cancers in population from Gujarat, West India	GCS/GCRI
2	Dr Prabhudas Patel Dr Ava Desai	VEGF family expression in cancer cervix and its prognostic significance	GCS/GCRI
3	Dr Jayendrakumar Patel	Significance of JAK-2, NPM1, C-KIT and FLT3 ITD and D835 mutations in leukemia patients	GCS/GCRI
4	Dr Franky Shah	Assessment of miRNA expression in breast cancer	GCS/GCRI
5	Dr Franky Shah	Role of vitamin D and vitamin Pathway genes in breast cancer	ICMR
6	Dr Prabhudas Patel Dr Hemangini Vora	Immunoscore colon cancer Multicentric Project  Biochemistry Research Division and Immunohistochemistry & Flowcytometry Division involved for multicentric project.	GCRI
<b>Cell Biology</b>			
7	Dr Prabhudas Patel	Clinical implication of MMPs, VEGF and hTERT in Imatinib resistant CML patients	GCS/GCRI
8	Dr Pina Trivedi	Study of Clinical and Prognostic Significance of Gene Rearrangements in Chronic Lymphocytic Leukemia	GCS/GCRI
9	Dr Prabhudas Patel	Clinical implications of multidrug resistance proteins in CML patients	GCS/GCRI
<b>Gynaecological Oncology</b>			
10	Dr Ruch Arora Dr Shilpa Patel	Risk of ovarian malignancy algorithm (ROMA) utilizing human epididymis protein-4 (HE-4) and CA-125 dual marker combination for prediction of ovarian cancer	GCS/GCRI
<b>Immunohistochemistry &amp; Flowcytometry</b>			
11	Dr Kruti Rajvik	Evaluation of effects of turmeric-A golden spice in non-smoker lung adenocarcinoma patients	GCS/GCRI
12	Dr Shalvi Mehta Dr Hemangini Vora	Evaluation of Ikaros mRNA and protein expression in B cell acute lymphoblastic leukemia	GCS/GCRI
13	Dr Hemangini Vora	Detection of cancer stem cells in breast cancer patients by multiparameters	GCS/GCRI
14	Dr Hemangini Vora	Detection of circulating tumor cells in breast cancer patients by multiparameter flowcytometry	GCS/GCRI
15	Dr Hemangini Vora	Detection of minimal residual disease in acute lymphoblastic leukemia by multicolor flowcytometry	GCS/GCRI

16	Dr Nupur Patel Dr Hemangini Vora	A study to determine role of miRNA 200 family molecules in Breast cancer patients exhibiting EMT	GCS/GCRI
17	Dr Priti Trivedi Dr Hemangini Vora	Determination of sensitivity of Napsin A and p40 in differential diagnosis of NSCLC	GCS/GCRI

### Medicinal Chemistry & Pharmacogenomics

18	Dr Apexa Raval	RTK signalling pathway and BRCA status in breast cancer subtypes	GCS/GCRI
19	Dr Rakesh Rawal	Assessment of epigenetic modifications in cellular differentiation biomarkers in oral Squamous cell carcinoma: In-vitro Approach	GCS/GCRI
20	Dr Rakesh Rawal	Detection of EGFR alteration from FFPE & Fresh Biopsy sample as NSCLC patients: A Pilot study	GCS/GCRI

### Medical Oncology

21	Dr Geeta Joshi	A Multi-Centre, Randomized, Double Blind, Parallel-Group, Comparative Clinical Trial to evaluate the Safety and Clinical Equivalence of Generic Clotrimazole Troche/Lozenges USP, 10mg (Unique Pharmaceutical Laboratories, India) to Clotrimazole Troche/Lozenges® 10mg (Roxane Laboratories Inc., USA) in subjects with Oropharyngeal Candidiasis	ThinQ Pharma
22	Dr Asha Anand	RLS/TP/2010/07 – “Prospective, multi-centric, open label, two arm, parallel group, active control, randomized, comparative clinical study to evaluate efficacy and safety of R-TPR-017 / MabThera® in patients with Non-Hodgkin's Lymphoma	Reliance Life Science
23	Dr Asha Anand	A prospective, randomized, multi-center study to compare the safety, tolerability and efficacy of Bevacizumab (ZydusCadila) with Bevacizumab (Avastin®) in non small cell lung cancer (NSCLC)	ZydusCadila
24	Dr Harsha Panchal	A phase II/III Open label Multicentric Randomised trial to determine the safety and efficacy of Non-pegylated Liposomal Doxorubicin (Nudoxa) at two different dose levels as compared to doxorubicin in patients with metastatic breast cancer	ZydusCadila
25	Dr Harsha Panchal	Protocol No. RLS/TP/2011/05 “Prospective, multi-centre, randomized, 6open-label, two arm, parallel group, active-control, comparative clinical study to evaluate efficacy, safety and pharmacokinetics of R-TPR-016/ Herceptin® (Herclon™) when given intravenously in patients with Metastatic HER2-Overexpressing Breast Cancer”	Reliance Life Sciences
26	Dr Harsha Panchal	A phase III randomized , Open label, multicentric, global study of MED14736 in combination with Tremelimumab therapy versus standard of care platinum based chemotherapy in first line treatment of patients with advanced or metastatic non small cell lung cancer (NSCLC) (NEPTUNE)	AstraZeneca

27	Dr Harsha Panchal	Reditux™ Registry to Compare Effectiveness, Safety, and Resource Utilization of Reditux™ vs. the Reference Medicinal Product to Treat Diffuse Large B-Cell Lymphoma and Chronic Lymphocytic Leukaemia in Routine Clinical Practice	Dr. Reddy's Laboratories Ltd.
28	Dr Apurva Patel	CLDK378A2301: A phase III multicenter, randomized study of oral LDK378 versus standard chemotherapy in previously untreated adult patients with ALK rearranged (ALK-positive), stage IIIB or IV, non-squamous non-small cell lung cancer	Novartis
29	Dr Sandip Shah	GP13-301 - A Randomized, Controlled, Double-Blind Phase III Trial to Compare the Efficacy, Safety and Pharmacokinetics of GP2013 plus CVP vs. MabThera® plus CVP, Followed by GP2013 or MabThera® Maintenance Therapy in Patients with Previously Untreated, Advanced Stage Follicular Lymphoma. Closed (International )	Sandoz-PPD
30	Dr Sonia Parikh	ABO8026 A prospective, multicenter, randomized, open-label, active-controlled, two-parallel groups, phase 3 study to compare the efficacy and safety of masitinib at 7.5 mg/kg/day to dacarbazine in the treatment of patients with non-resectable or metastatic stage 3 or stage 4 melanoma carrying a mutation in the juxta membrane domain of c-kit	Maya Clinicals

### Molecular Endocrinology

31	Dr Nandita Ghosh	Role of molecular markers in predicting treatment response and prognosis in patients with colorectal cancer	GCS/GCRI
32	Dr Nandita Ghosh	Molecular markers of Wnt signalling pathway in breast cancer: A preliminary study	GCS/GCRI
33	Dr Nandita Ghosh	Circulating levels of miRNA-21 and miRNA-221 as biomarkers in colorectal cancer	GCS/GCRI
34	Dr Nandita Ghosh	MicroRNA profiling in human colorectal cancer- a pilot study	GUJCOST

### Radiotherapy

35	Dr Pooja Nandwani Patel	Study of sequential volumetric changes of parotid gland in early oropharyngeal carcinoma patients treated by Image Guided Radiation Therapy	GCRI
36		Comparison of induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in locally advanced nasopharyngeal cancer	GCRI
37	Dr Jigna Bhattacharya	Epidemiological study of patients attending the Radiotherapy department	GCS/GCRI
38	Dr Maitrik Mehta	Comparison of Involved Site Radiotherapy vs Involved Field Radiotherapy in Hodgkins Lymphoma with CT Based Conformal Plan	GCS/GCRI